Advertisement

Psychopharmacology

, Volume 216, Issue 1, pp 75–84 | Cite as

Fluoxetine regulates the expression of neurotrophic/growth factors and glucose metabolism in astrocytes

  • Igor Allaman
  • Hubert Fiumelli
  • Pierre J. Magistretti
  • Jean-Luc Martin
Original Investigation

Abstract

Rationale

The pharmacological actions of most antidepressants are ascribed to the modulation of serotonergic and/or noradrenergic transmission in the brain. During therapeutic treatment for major depression, fluoxetine, one of the most commonly prescribed selective serotonin reuptake inhibitor (SSRI) antidepressants, accumulates in the brain, suggesting that fluoxetine may interact with additional targets. In this context, there is increasing evidence that astrocytes are involved in the pathophysiology of major depression.

Objectives

The aim of this study was to examine the effects of fluoxetine on the expression of neurotrophic/growth factors that have antidepressant properties and on glucose metabolism in cultured cortical astrocytes.

Results

Treatment of astrocytes with fluoxetine and paroxetine, another SSRI antidepressant, upregulated brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), and VGF mRNA expression. In contrast, the tricyclic antidepressants desipramine and imipramine did not affect the expression of these neurotrophic/growth factors. Analysis of the effects of fluoxetine on glucose metabolism revealed that fluoxetine reduces glycogen levels and increases glucose utilization and lactate release by astrocytes. Similar data were obtained with paroxetine, whereas imipramine and desipramine did not regulate glucose metabolism in this glial cell population. Our results also indicate that the effects of fluoxetine and paroxetine on glucose utilization, lactate release, and expression of BDNF, VEGF, and VGF are not mediated by serotonin-dependent mechanisms.

Conclusions

These data suggest that, by increasing the expression of specific astrocyte-derived neurotrophic factors and lactate release from astrocytes, fluoxetine may contribute to normalize the trophic and metabolic support to neurons in major depression.

Keywords

Antidepressants Growth factors Glia Serotonin Lactate Glycogen 

Notes

Acknowledgments

The authors are grateful to Cendrine Barrière Borgioni and Evelyne Ruchti for valuable technical assistance. This work was supported by the Swiss National Science Foundation grants 31003A-124783 (to JLM) and 3100AO-108336/1 (to PJM), the Désirée and Niels Yde's Foundation (to JLM and PJM), and the Swiss Academy of Medical Sciences (to JLM and PJM). The authors have no financial relationship with the Swiss National Science Foundation, the Désirée and Niels Yde's Foundation, and the Swiss Academy of Medical Sciences. All experiments comply with the Swiss federal act on animal protection and the Swiss animal protection ordinance.

References

  1. Alder J, Thakker-Varia S, Bangasser DA, Kuroiwa M, Plummer MR, Shors TJ, Black IB (2003) Brain-derived neurotrophic factor-induced gene expression reveals novel actions of VGF in hippocampal synaptic plasticity. J Neurosci 23:10800–10808PubMedGoogle Scholar
  2. Allaman I, Gavillet M, Belanger M, Laroche T, Viertl D, Lashuel HA, Magistretti PJ (2010) Amyloid-beta aggregates cause alterations of astrocytic metabolic phenotype: impact on neuronal viability. J Neurosci 30:3326–3338PubMedCrossRefGoogle Scholar
  3. Allaman I, Pellerin L, Magistretti PJ (2004) Glucocorticoids modulate neurotransmitter-induced glycogen metabolism in cultured cortical astrocytes. J Neurochem 88:900–908PubMedCrossRefGoogle Scholar
  4. Allen NJ, Barres BA (2005) Signaling between glia and neurons: focus on synaptic plasticity. Curr Opin Neurobiol 15:542–548PubMedCrossRefGoogle Scholar
  5. Banasr M, Duman RS (2008) Glial loss in the prefrontal cortex is sufficient to induce depressive-like behaviors. Biol Psychiatry 64:863–870PubMedCrossRefGoogle Scholar
  6. Barker AJ, Ullian EM (2010) Astrocytes and synaptic plasticity. Neuroscientist 16:40–50PubMedCrossRefGoogle Scholar
  7. Berton O, Nestler EJ (2006) New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 7:137–151PubMedCrossRefGoogle Scholar
  8. Bianchi MT (2008) Non-serotonin anti-depressant actions: direct ion channel modulation by SSRIs and the concept of single agent poly-pharmacy. Med Hypotheses 70:951–956PubMedGoogle Scholar
  9. Bolo NR, Hode Y, Nedelec JF, Laine E, Wagner G, Macher JP (2000) Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. Neuropsychopharmacology 23:428–438PubMedCrossRefGoogle Scholar
  10. Bonni A, Ginty DD, Dudek H, Greenberg ME (1995) Serine 133-phosphorylated CREB induces transcription via a cooperative mechanism that may confer specificity to neurotrophin signals. Mol Cell Neurosci 6:168–183PubMedCrossRefGoogle Scholar
  11. Bremner JD, Vythilingam M, Vermetten E, Nazeer A, Adil J, Khan S, Staib LH, Charney DS (2002) Reduced volume of orbitofrontal cortex in major depression. Biol Psychiatry 51:273–279PubMedCrossRefGoogle Scholar
  12. Brown AM, Ransom BR (2007) Astrocyte glycogen and brain energy metabolism. Glia 55:1263–1271PubMedCrossRefGoogle Scholar
  13. Cater HL, Benham CD, Sundstrom LE (2001) Neuroprotective role of monocarboxylate transport during glucose deprivation in slice cultures of rat hippocampus. J Physiol 531:459–466PubMedCrossRefGoogle Scholar
  14. Cattaneo A, Sesta A, Calabrese F, Nielsen G, Riva MA, Gennarelli M (2010) The expression of VGF is reduced in leukocytes of depressed patients and it is restored by effective antidepressant treatment. Neuropsychopharmacology 35:1423–1428PubMedCrossRefGoogle Scholar
  15. Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT (2001) Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 50:260–265PubMedCrossRefGoogle Scholar
  16. Choudary PV, Molnar M, Evans SJ, Tomita H, Li JZ, Vawter MP, Myers RM, Bunney WE Jr, Akil H, Watson SJ, Jones EG (2005) Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci USA 102:15653–15658PubMedCrossRefGoogle Scholar
  17. Cotter D, Mackay D, Chana G, Beasley C, Landau S, Everall IP (2002) Reduced neuronal size and glial cell density in area 9 of the dorsolateral prefrontal cortex in subjects with major depressive disorder. Cereb Cortex 12:386–394PubMedCrossRefGoogle Scholar
  18. Czeh B, Simon M, Schmelting B, Hiemke C, Fuchs E (2006) Astroglial plasticity in the hippocampus is affected by chronic psychosocial stress and concomitant fluoxetine treatment. Neuropsychopharmacology 31:1616–1626PubMedCrossRefGoogle Scholar
  19. Drevets WC (2000a) Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression. Prog Brain Res 126:413–431CrossRefGoogle Scholar
  20. Drevets WC (2000b) Neuroimaging studies of mood disorders. Biol Psychiatry 48:813–829CrossRefGoogle Scholar
  21. Drevets WC (2001) Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. Curr Opin Neurobiol 11:240–249PubMedCrossRefGoogle Scholar
  22. Dwivedi Y, Rizavi HS, Conley RR, Roberts RC, Tamminga CA, Pandey GN (2003) Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry 60:804–815PubMedCrossRefGoogle Scholar
  23. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669–676PubMedCrossRefGoogle Scholar
  24. Furutani K, Ohno Y, Inanobe A, Hibino H, Kurachi Y (2009) Mutational and in silico analyses for antidepressant block of astroglial inward-rectifier Kir4.1 channel. Mol Pharmacol 75:1287–1295PubMedCrossRefGoogle Scholar
  25. Ghosh A, Carnahan J, Greenberg ME (1994) Requirement for BDNF in activity-dependent survival of cortical neurons. Science 263:1618–1623PubMedCrossRefGoogle Scholar
  26. Greene J, Banasr M, Lee B, Warner-Schmidt J, Duman RS (2009) Vascular endothelial growth factor signaling is required for the behavioral actions of antidepressant treatment: pharmacological and cellular characterization. Neuropsychopharmacology 34:2459–2468PubMedCrossRefGoogle Scholar
  27. Guo S, Arai K, Stins MF, Chuang DM, Lo EH (2009) Lithium upregulates vascular endothelial growth factor in brain endothelial cells and astrocytes. Stroke 40:652–655PubMedCrossRefGoogle Scholar
  28. Halassa MM, Haydon PG (2010) Integrated brain circuits: astrocytic networks modulate neuronal activity and behavior. Annu Rev Physiol 72:335–355PubMedCrossRefGoogle Scholar
  29. Hashimoto K, Sawa A, Iyo M (2007) Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 62:1310–1316PubMedCrossRefGoogle Scholar
  30. Henry ME, Schmidt ME, Hennen J, Villafuerte RA, Butman ML, Tran P, Kerner LT, Cohen B, Renshaw PF (2005) A comparison of brain and serum pharmacokinetics of R-fluoxetine and racemic fluoxetine: a 19-F MRS study. Neuropsychopharmacology 30:1576–1583PubMedCrossRefGoogle Scholar
  31. Hisaoka K, Takebayashi M, Tsuchioka M, Maeda N, Nakata Y, Yamawaki S (2007) Antidepressants increase glial cell line-derived neurotrophic factor production through monoamine-independent activation of protein tyrosine kinase and extracellular signal-regulated kinase in glial cells. J Pharmacol Exp Ther 321:148–157PubMedCrossRefGoogle Scholar
  32. Hoshaw BA, Malberg JE, Lucki I (2005) Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects. Brain Res 1037:204–208PubMedCrossRefGoogle Scholar
  33. Hunsberger JG, Newton SS, Bennett AH, Duman CH, Russell DS, Salton SR, Duman RS (2007) Antidepressant actions of the exercise-regulated gene VGF. Nat Med 13:1476–1482PubMedCrossRefGoogle Scholar
  34. Jin K, Mao XO, Greenberg DA (2006) Vascular endothelial growth factor stimulates neurite outgrowth from cerebral cortical neurons via Rho kinase signaling. J Neurobiol 66:236–242PubMedCrossRefGoogle Scholar
  35. Jin K, Zhu Y, Sun Y, Mao XO, Xie L, Greenberg DA (2002) Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc Natl Acad Sci USA 99:11946–11950PubMedCrossRefGoogle Scholar
  36. Jones KR, Farinas I, Backus C, Reichardt LF (1994) Targeted disruption of the BDNF gene perturbs brain and sensory neuron development but not motor neuron development. Cell 76:989–999PubMedCrossRefGoogle Scholar
  37. Khaibullina AA, Rosenstein JM, Krum JM (2004) Vascular endothelial growth factor promotes neurite maturation in primary CNS neuronal cultures. Brain Res Dev Brain Res 148:59–68PubMedCrossRefGoogle Scholar
  38. Khawaja X, Xu J, Liang JJ, Barrett JE (2004) Proteomic analysis of protein changes developing in rat hippocampus after chronic antidepressant treatment: implications for depressive disorders and future therapies. J Neurosci Res 75:451–460PubMedCrossRefGoogle Scholar
  39. Krum JM, Mani N, Rosenstein JM (2002) Angiogenic and astroglial responses to vascular endothelial growth factor administration in adult rat brain. Neuroscience 110:589–604PubMedCrossRefGoogle Scholar
  40. Lewin GR, Barde YA (1996) Physiology of the neurotrophins. Annu Rev Neurosci 19:289–317PubMedCrossRefGoogle Scholar
  41. Lindholm D, Carroll P, Tzimagiogis G, Thoenen H (1996) Autocrine-paracrine regulation of hippocampal neuron survival by IGF-1 and the neurotrophins BDNF, NT-3 and NT-4. Eur J Neurosci 8:1452–1460PubMedCrossRefGoogle Scholar
  42. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402–408PubMedCrossRefGoogle Scholar
  43. Magistretti PJ (2008) Brain energy metabolism. In: Squire LR, Berg D, Bloom FE, Du Lac S, Ghosh A, Spitzer NC (eds) Fundamental neuroscience, 3rd edn. Academic Press, San Diego, pp 271–293Google Scholar
  44. Magistretti PJ, Manthorpe M, Bloom FE, Varon S (1983) Functional receptors for vasoactive intestinal polypeptide in cultured astroglia from neonatal rat brain. Regul Pept 6:71–80PubMedCrossRefGoogle Scholar
  45. Magistretti PJ, Sorg O, Martin JL (1993) Regulation of glycogen metabolism in astrocytes: physiological, pharmacological, and pathological aspects. In: Murphy S (ed) Astrocytes: pharmacology and function. Academic Press, San Diego, pp 243–265Google Scholar
  46. Malberg JE, Monteggia LM (2008) VGF, a new player in antidepressant action? Sci Signal 1:e19CrossRefGoogle Scholar
  47. Mallei A, Shi B, Mocchetti I (2002) Antidepressant treatments induce the expression of basic fibroblast growth factor in cortical and hippocampal neurons. Mol Pharmacol 61:1017–1024PubMedCrossRefGoogle Scholar
  48. Maus M, Marin P, Israel M, Glowinski J, Premont J (1999) Pyruvate and lactate protect striatal neurons against N-methyl-D-aspartate-induced neurotoxicity. Eur J Neurosci 11:3215–3224PubMedCrossRefGoogle Scholar
  49. Mayberg HS, Brannan SK, Tekell JL, Silva JA, Mahurin RK, McGinnis S, Jerabek PA (2000) Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol Psychiatry 48:830–843PubMedCrossRefGoogle Scholar
  50. McAllister AK, Katz LC, Lo DC (1996) Neurotrophin regulation of cortical dendritic growth requires activity. Neuron 17:1057–1064PubMedCrossRefGoogle Scholar
  51. McAllister AK, Lo DC, Katz LC (1995) Neurotrophins regulate dendritic growth in developing visual cortex. Neuron 15:791–803PubMedCrossRefGoogle Scholar
  52. Newton SS, Collier EF, Hunsberger J, Adams D, Terwilliger R, Selvanayagam E, Duman RS (2003) Gene profile of electroconvulsive seizures: induction of neurotrophic and angiogenic factors. J Neurosci 23:10841–10851PubMedGoogle Scholar
  53. Nibuya M, Morinobu S, Duman RS (1995) Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 15:7539–7547PubMedGoogle Scholar
  54. Ongur D, Drevets WC, Price JL (1998) Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA 95:13290–13295PubMedCrossRefGoogle Scholar
  55. Pellerin L, Bouzier-Sore AK, Aubert A, Serres S, Merle M, Costalat R, Magistretti PJ (2007) Activity-dependent regulation of energy metabolism by astrocytes: An update. Glia 55:1251–1262PubMedCrossRefGoogle Scholar
  56. Perea G, Navarrete M, Araque A (2009) Tripartite synapses: astrocytes process and control synaptic information. Trends Neurosci 32:421–431PubMedCrossRefGoogle Scholar
  57. Rajkowska G (2000) Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol Psychiatry 48:766–777PubMedCrossRefGoogle Scholar
  58. Rajkowska G, Miguel-Hidalgo JJ (2007) Gliogenesis and glial pathology in depression. CNS Neurol Disord Drug Targets 6:219–233PubMedCrossRefGoogle Scholar
  59. Rajkowska G, Miguel-Hidalgo JJ, Wei J, Dilley G, Pittman SD, Meltzer HY, Overholser JC, Roth BL, Stockmeier CA (1999) Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 45:1085–1098PubMedCrossRefGoogle Scholar
  60. Rosenstein JM, Mani N, Khaibullina A, Krum JM (2003) Neurotrophic effects of vascular endothelial growth factor on organotypic cortical explants and primary cortical neurons. J Neurosci 23:11036–11044PubMedGoogle Scholar
  61. Rouach N, Koulakoff A, Abudara V, Willecke K, Giaume C (2008) Astroglial metabolic networks sustain hippocampal synaptic transmission. Science 322:1551–1555PubMedCrossRefGoogle Scholar
  62. Salton SR, Ferri GL, Hahm S, Snyder SE, Wilson AJ, Possenti R, Levi A (2000) VGF: a novel role for this neuronal and neuroendocrine polypeptide in the regulation of energy balance. Front Neuroendocrinol 21:199–219PubMedCrossRefGoogle Scholar
  63. Sanacora G, Gueorguieva R, Epperson CN, Wu YT, Appel M, Rothman DL, Krystal JH, Mason GF (2004) Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 61:705–713PubMedCrossRefGoogle Scholar
  64. Schurr A, Payne RS, Miller JJ, Rigor BM (1997a) Brain lactate is an obligatory aerobic energy substrate for functional recovery after hypoxia: further in vitro validation. J Neurochem 69:423–426CrossRefGoogle Scholar
  65. Schurr A, Payne RS, Miller JJ, Rigor BM (1997b) Glia are the main source of lactate utilized by neurons for recovery of function posthypoxia. Brain Res 774:221–224CrossRefGoogle Scholar
  66. Sheline YI (2003) Neuroimaging studies of mood disorder effects on the brain. Biol Psychiatry 54:338–352PubMedCrossRefGoogle Scholar
  67. Shirayama Y, Chen AC, Nakagawa S, Russell DS, Duman RS (2002) Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 22:3251–3261PubMedGoogle Scholar
  68. Si X, Miguel-Hidalgo JJ, O'Dwyer G, Stockmeier CA, Rajkowska G (2004) Age-dependent reductions in the level of glial fibrillary acidic protein in the prefrontal cortex in major depression. Neuropsychopharmacology 29:2088–2096PubMedCrossRefGoogle Scholar
  69. Sickmann HM, Walls AB, Schousboe A, Bouman SD, Waagepetersen HS (2009) Functional significance of brain glycogen in sustaining glutamatergic neurotransmission. J Neurochem 109(Suppl 1):80–86PubMedCrossRefGoogle Scholar
  70. Slezak M, Pfrieger FW (2003) New roles for astrocytes: regulation of CNS synaptogenesis. Trends Neurosci 26:531–535PubMedCrossRefGoogle Scholar
  71. Thakker-Varia S, Alder J (2009) Neuropeptides in depression: role of VGF. Behav Brain Res 197:262–278PubMedCrossRefGoogle Scholar
  72. Thakker-Varia S, Krol JJ, Nettleton J, Bilimoria PM, Bangasser DA, Shors TJ, Black IB, Alder J (2007) The neuropeptide VGF produces antidepressant-like behavioral effects and enhances proliferation in the hippocampus. J Neurosci 27:12156–12167PubMedCrossRefGoogle Scholar
  73. Turner CA, Gula EL, Taylor LP, Watson SJ, Akil H (2008) Antidepressant-like effects of intracerebroventricular FGF2 in rats. Brain Res 1224:63–68PubMedCrossRefGoogle Scholar
  74. Wada T, Haigh JJ, Ema M, Hitoshi S, Chaddah R, Rossant J, Nagy A, van der Kooy D (2006) Vascular endothelial growth factor directly inhibits primitive neural stem cell survival but promotes definitive neural stem cell survival. J Neurosci 26:6803–6812PubMedCrossRefGoogle Scholar
  75. Wang DD, Bordey A (2008) The astrocyte odyssey. Prog Neurobiol 86:342–367PubMedGoogle Scholar
  76. Warner-Schmidt JL, Duman RS (2007) VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants. Proc Natl Acad Sci USA 104:4647–4652PubMedCrossRefGoogle Scholar
  77. Warner-Schmidt JL, Duman RS (2008) VEGF as a potential target for therapeutic intervention in depression. Curr Opin Pharmacol 8:14–19PubMedCrossRefGoogle Scholar
  78. Wong DT, Perry KW, Bymaster FP (2005) Case history: the discovery of fluoxetine hydrochloride (Prozac). Nat Rev Drug Discov 4:764–774PubMedGoogle Scholar
  79. Wong ML, Licinio J (2004) From monoamines to genomic targets: a paradigm shift for drug discovery in depression. Nat Rev Drug Discov 3:136–151PubMedCrossRefGoogle Scholar
  80. Zhang X, Peng L, Chen Y, Hertz L (1993) Stimulation of glycogenolysis in astrocytes by fluoxetine, an antidepressant acting like 5-HT. NeuroReport 4:1235–1238PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Igor Allaman
    • 1
  • Hubert Fiumelli
    • 2
  • Pierre J. Magistretti
    • 1
    • 3
  • Jean-Luc Martin
    • 2
    • 3
  1. 1.Laboratory of Neuroenergetics and Cellular Dynamics, Brain Mind InstituteEcole Polytechnique Fédérale de Lausanne (EPFL)LausanneSwitzerland
  2. 2.Department of PhysiologyUniversity of LausanneLausanneSwitzerland
  3. 3.Department of Psychiatry-CHUVCenter for Psychiatric NeurosciencePrilly-LausanneSwitzerland

Personalised recommendations